UBS Group
IART icon

UBS Group’s Integra LifeSciences IART Stock Holding History

UBS Group’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-55,000
Closed -$2.26M – 9677
2023
Q2 		$2.26M Sell
55,000
-53,000
-49% -$2.55M ﹤0.01% 3405
2023
Q1 		$6.2M Buy
+108,000
New +$6.09M ﹤0.01% 2314

Other funds holding IART

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

UBS Group's IART Position: Q2 2026 in Review

UBS Group reduced its Integra LifeSciences (IART) stake by 32% in Q2 2026, selling an estimated $901K and leaving 138,320 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #4911.

UBS Group first reported a position in IART in Q4 2014 and has held it in 47 quarters since. The position peaked at $5.08M in Q4 2025. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • UBS Group held 138,320 shares of Integra LifeSciences worth $2.48M as of Q2 2026.
  • UBS Group sold 64,425 Integra LifeSciences shares in Q2 2026, an estimated $901K.
  • Integra LifeSciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4911 holding.
  • UBS Group first reported a position in Integra LifeSciences in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Integra LifeSciences position peaked at $5.08M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.